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te previously reported that patients undergoing interhospital
ransfer for primary percutaneous coronary intervention (PCI) in
he U.S. rarely met national guidelines-based recommendations of
oor-to-balloon times of 90 min using data from 1999 to 2002
n the National Registry of Myocardial Infarction (NRMI) (1).
he median “total” door-to-balloon time, that is, the time from
rrival at the first hospital to initial balloon inflation at the PCI
ospital, in these patients was 180 min and only 4.2% had times
90 min. Since the publication of that report, there have been
idespread efforts to improve timely access to primary PCI
hrough the establishment of regionalized networks of hospitals for
T-segment elevation myocardial infarction (STEMI) (2,3).
owever, more contemporary data on total door-to-balloon times
n patients undergoing interhospital transfer for primary PCI have
et to be reported.
We used 2005 and 2006 data from the American College of
ardiology National Cardiovascular Data Registry’s CathPCI
egistry. Details of hospitals and data collection methods used
y the National Cardiovascular Data Registry have been previ-
usly described (4). We included all catheterization laboratory
isits of STEMI patients undergoing primary PCI after inter-
ospital transfer (n  22,019). To narrow our study population
urther, we excluded catheterization laboratory visits by pa-
ients: 1) who presented to the hospital more than 12 h after
ymptom onset (n  2,993) or with uncertain time of symptom
nset (n  453); 2) who received any fibrinolytic therapy before
rrival in the cardiac catheterization laboratory (n  2,622); 3)
ith unknown or invalid date/time of reference for hospital
rrival or PCI (n  852); 4) with door-to-balloon times 12 h
n  1,677); and 5) with any combination of the above
xclusions (n  6,874). This restricted our study population to
5,145 catheterization laboratory visits in 15,049 patients at
91 hospitals.
Our primary end point was “total” door-to-balloon time, which
as defined as the time of arrival at the first hospital to the time of
nitial balloon inflation at the PCI hospital. We also evaluated: 1)
oor-to-door time (time of arrival at the initial hospital to time of
rrival at the PCI hospital); and 2) PCI hospital door-to-balloon
ime (time of arrival at the PCI hospital to time of the first balloon
nflation at the PCI hospital). Univariable analyses were used to
eport characteristics of the study population and the distribution
f these end points.
The mean age of the study population was 60.5 years; 29.0%
ere women, 88.3% were white, and 20.8% had diabetesellitus. In addition, 31.6% of patients arrived at the first
ospital on weekdays between 8 AM and 4 PM, 14.6% presented
6 h after symptom onset, and 10.6% were in cardiogenic
hock. The median time from arrival in the initial hospital to
he first balloon inflation time at the PCI hospital (i.e., total
oor-to-balloon time) was 152 min (interquartile range 116 to
11 min). Total door-to-balloon time was 2 h in 27.7% of
atients, between 2 and 4 h in 53.9% of patients, and 4 h in
8.4% of patients (Fig. 1). Only 8.6% of patients had total
oor-to-balloon times 90 min. The median door-to-door and
CI hospital door-to-balloon times were 109 and 38 min,
espectively.
The use of primary PCI in patients with STEMI is rising in the
.S. (5). However, there continue to be concerns about its
ffectiveness in patients undergoing interhospital transfer, given
he potential risks of delays in time-to-reperfusion. Although
e previously reported that such delays are common, those
esults used data collected before the publication of the
ANAMI-2 (Danish Multicenter Randomized Study on
hrombolytic Therapy Versus Acute Coronary Angioplasty in
cute Myocardial Infarction-2) trial (6). This landmark study,
hich found that interhospital transfer for primary PCI is both
easible and efficacious within the controlled setting of a clinical
rial, has prompted local and national efforts in the U.S. to improve
Figure 1 Distribution of “Total” Door-to-Balloon Times
in Patients Undergoing Transfer for Primary PCI
Total balloon time refers to the time from arrival at the first hospital to first bal-
loon inflation at the percutaneous coronary intervention (PCI) hospital. The pro-
portion of patients with total door-to-balloon times 90 min is highlighted by
the solid bar.
t
o
i
d
i
f
d
e
a
m
h
a
a
o
T
h
i
i
t
f
*
*
U
3
1
A
E
H
Y
J
B
f
P
B
C
K
R
1
2
3
4
5
6
T
P
N
a
d
c
b
a
p
i
c
h
p
p
w
A
s
a
2
2443JACC Vol. 51, No. 25, 2008 Correspondence
June 24, 2008:2442–5imely access to primary PCI by establishing regionalized networks
f hospitals for STEMI.
In this context, the present analysis adds important new
nformation to the literature. Our findings suggest shorter total
oor-to-balloon times in transfer patients during the interven-
ng few years (i.e., 152 min vs. 180 min). However, we also
ound that many patients still have marked delays in total
oor-to-balloon times and that few reach the benchmark
stablished by national guidelines. Compared with the previous
nalysis, total door-to-balloon times were shorter because of
ore rapid door-to-door times (109 min vs. 120 min) and PCI
ospital door-to-balloon times (38 min vs. 53 min). Of course,
ny direct comparisons between the present and previous
nalyses should be done with caution, owing to the involvement
f different hospitals and types of patients between registries.
he present analysis, for example, included more nonurban
ospitals as well as patients with cardiogenic shock. Finally, it
s important to note that these hospitals participated voluntarily
n the CathPCI registry, a national quality improvement regis-
ry. These hospitals therefore may present a “best”-case scenario
or transfer patients.
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studies, our results align well with those of Narducci et al. (1),
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infarction. N Engl J Med 2003;349:733–42.Letters to the Editorelomerase-Positive Neutrophils:
laque “Survivors” and Restenosis
arducci et al. (1) recently demonstrated high telomerase
ctivity in polymorphonuclear neutrophilic leukocytes (PMNs)
erived from plaques in patients with unstable angina. In
ontrast, PMNs from stable coronary plaques and peripheral
lood samples had minimal telomerase activity. The authors’
nalysis relied on a novel, though indirect, method of acquiring
laque PMNs; specifically, they studied cells isolated by wash-
ng angioplasty balloons. Immunohistochemical techniques
onfirmed that 90% of adherent cells were neutrophils. We
ave previously reported a different strategy for analyzing
laque telomerase activity (2). Using tissue acquired from 23
atients undergoing directional coronary atherectomy (DCA),
e found that 8 of 23 (35%) were positive for telomerase (2).
ll but 1 of these patients presented with an acute coronary
yndrome. Although the quantification of the telomeric repeat
mplification protocol (TRAP) was performed differently in theho found high telomerase activity in 6 of 20 (30%) of their
atients with unstable angina. Because DCA samples contain
ells other than PMNs, such as vascular smooth muscle
ells, endothelial cells, and macrophages, the similar rates of
RAP positivity would suggest that PMNs are the major source
f telomerase in the unstable plaque. However, additional
tudies using in situ assays are warranted before this conclusion
s firmly established. The infiltration of coronary plaques by
MNs with persistent or reactivated telomerase could promote
n exaggerated local inflammatory response and lead to plaque
nstability. It is also plausible that PMN-derived telomerase
ctivity promotes restenosis (3). Of note in this regard, we
ound that patients with telomerase-positive DCA tissue were
ore likely to experience clinical or angiographic evidence of
estenosis (2).
Thus, using 2 different strategies, 30% to 35% of unstable
oronary plaques have “survivors” or telomerase-positive cells (1,2).
arducci et al. (1) provide strong support that these cells are
redominantly PMNs. Their study could provide a novel strategy
or identifying patients at increased risk for adverse events,
ncluding restenosis.
